HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy and safety of two single-pill fixed-dose combinations of angiotensin II receptor blockers/calcium channel blockers in hypertensive patients (EXAMINER study).

AbstractBACKGROUND:
There is some controversy regarding which single-pill fixed-dose combinations of angiotensin II type 1 receptor blockers (ARBs) and calcium channel blockers (CCBs) are effective at reducing blood pressure (BP).
METHODS:
Sixty hypertensive patients who received a single-pill fixed-dose combination of valsartan 80 mg/day and amlodipine 5 mg/day were enrolled (UMIN Registration 000013460). They were randomly divided into two treatment groups [single-pill fixed-dose combination therapy with valsartan 80 mg/day and amlodipine 5 mg/day (Val/Am group), or irbesartan 100 mg/day and amlodipine 5 mg/day (Irb/Am group)] and treated for 16 weeks. If the patient did not reach the target office BP at 8 weeks, they received double doses of amlodipine (10 mg/day).
RESULTS:
In the Irb/Am group, systolic BP (SBP) and diastolic BP (DBP) were significantly decreased at 16 weeks. There were no significant changes in SBP or DBP in the Val/Am group. In the Irb/Am group, serum uric acid (UA) was significantly decreased at 8 weeks and patients who had hyperuricemia showed significantly decreased serum UA at 16 weeks. In addition, the levels of triglycerides (TG) were significantly decreased at 16 weeks in the Irb/Am group.
CONCLUSION:
A single-pill fixed-dose combination therapy with irbesartan 100 mg/day and amlodipine 5 mg/day was superior to the combination of valsartan 80 mg/day and amlodipine 5 mg/day with respect to significant decreases in BP, serum UA and TG in patients with hypertension.
AuthorsKota Motozato, Shin-Ichiro Miura, Yuhei Shiga, Takaaki Kusumoto, Sen Adachi, Takeshi Inoue, Kazuaki Fujisawa, Keijiro Saku
JournalClinical and experimental hypertension (New York, N.Y. : 1993) (Clin Exp Hypertens) Vol. 38 Issue 1 Pg. 45-50 ( 2016) ISSN: 1525-6006 [Electronic] England
PMID26268636 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Antihypertensive Agents
  • Biphenyl Compounds
  • Drug Combinations
  • Tetrazoles
  • Triglycerides
  • Amlodipine
  • Uric Acid
  • Valsartan
  • Irbesartan
Topics
  • Aged
  • Amlodipine (administration & dosage, adverse effects)
  • Antihypertensive Agents (administration & dosage, adverse effects)
  • Biphenyl Compounds (administration & dosage, adverse effects)
  • Blood Pressure (drug effects)
  • Dose-Response Relationship, Drug
  • Drug Combinations
  • Drug Monitoring
  • Female
  • Humans
  • Hypertension (blood, diagnosis, drug therapy, physiopathology)
  • Irbesartan
  • Male
  • Middle Aged
  • Tetrazoles (administration & dosage, adverse effects)
  • Treatment Outcome
  • Triglycerides (blood)
  • Uric Acid (blood)
  • Valsartan (administration & dosage, adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: